Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625.

Front Oncol · 2023 · PMC9909012 · PMID 36776298

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0800

boldest claim

The sentences

borderline significantp= 0.05actually significant

nRCBV was not predictive of PFS at week 16 (p=0.09), but 2D-T1 response status was borderline significant (p= 0.05) ( Figure 4 ); however, PFS did not differ by 2D-T1 response status among the entire cohort of 2D-T1 non-progressors at week 16 (p=0.66, n=45), of which this small number of patients also with DSC-MRI data (n=7) was a subset.

also in 11,409 other papers

did not reach statistical significancep=0.08so close (0.05 < p ≤ 0.1)

not reached, p=0.008), although the same comparison did not reach statistical significance for nRCBV (p=0.08) ( Figure 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.